Immunohistological evaluation of patients treated with intra-arterial chemoradiotherapy and surgery for oral cancer

Preoperative intra-arterial chemoradiotherapy (IACRT) can improve the outcome and reduce the extent of surgery in patients with advanced oral cancer. However, the response to this regimen varies among patients, which may be related to the immune status of the tumor. We investigated the effects of pr...

Full description

Saved in:
Bibliographic Details
Published in:Medical molecular morphology 2023-12, Vol.56 (4), p.288-296
Main Authors: Ikeuchi, Yutaro, Someya, Masanori, Hasegawa, Tomokazu, Saito, Masato, Mafune, Shoh, Tsuchiya, Takaaki, Kitagawa, Mio, Gocho, Toshio, Dehari, Hironari, Ogi, Kazuhiro, Sasaki, Takanori, Hirohashi, Yoshihiko, Torigoe, Toshihiko, Hirokawa, Naoki, Miyazaki, Akihiro, Sakata, Koh-ichi
Format: Article
Language:English
Subjects:
Anatomy
Apoptosis
Biopsy
CD8 antigen
Chemoradiotherapy
Chemotherapy
Foxp3 protein
Immune status
Lymphocytes
Lymphocytes T
Medicine
Medicine & Public Health
Metastases
Microenvironments
Molecular Medicine
Oral cancer
Original Paper
Pathology
Patients
PD-L1 protein
Radiation therapy
Surgery
Tumor cells
Tumor-infiltrating lymphocytes
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preoperative intra-arterial chemoradiotherapy (IACRT) can improve the outcome and reduce the extent of surgery in patients with advanced oral cancer. However, the response to this regimen varies among patients, which may be related to the immune status of the tumor. We investigated the effects of proteins involved in tumor immunity on the outcomes of combined IACRT and surgery for oral cancer. We examined CD8 + and FoxP3 + tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression on immune cells and tumor cells in pretreatment biopsy samples from 69 patients diagnosed with oral cancer treated with IACRT at our institution during 2000–2020. Patients with abundant CD8 + TILs had significantly better 5-year disease-specific survival (DSS) compared to that of patients with less infiltration of these cells ( P  = 0.016). Patients with higher FoxP3 + T-cells invasion had significantly better DSS compared to that of less FoxP3 ( P  = 0.005). Patients with high PD-L1 expression in tumor cells and immune cells had significantly better DSS than that of patients with low PD-L1 expression in these cells ( P  = 0.009 and P  = 0.025, respectively). Collectively, these results suggest that the tumor immune microenvironment could affect outcomes of IACRT treatment in oral cancer.
ISSN:1860-1480
1860-1499
DOI:10.1007/s00795-023-00367-8